
This study compares the effectiveness of SGLT2 inhibitors versus DPP4 inhibitors on major liver outcomes in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Analysis of 44,651 patients revealed no significant difference in liver outcome risks between the two drug classes. Clinicians should consider overall patient conditions when choosing between these therapies.
Like
Save
Share